The global gene therapy market for Severe Combined Immunodeficiency (SCID) is poised for significant growth, projected to reach $2 billion by 2034. Driven by advancements in gene therapy techniques, the market is witnessing an increase in collaborations and partnerships between pharmaceutical companies and research institutions. This article dives into the key trends shaping the market, highlighting successful treatments like Strimvelis and the potential of gene editing for SCID.
A recent case of a child in Kerala dying from vaccine-derived poliovirus (VDPV) has raised concerns about the safety of polio vaccination in immunocompromised individuals. Experts discuss the differences between wild poliovirus and VDPV, the transmission of the virus, and the importance of newborn screening for immunodeficiencies. They also highlight advancements in antiviral treatments and emphasize the need for public health guidelines to adapt to these emerging risks.
